Background
Methods
Patient and data collection
Surgical technique
IABP indication and management
ECMO indication and management
Statistical analysis
Results
All | MIMVS | FS | P value | |
---|---|---|---|---|
n = 5901 | n = 3389 | n = 2512 | ||
Male gender | 52.5% | 45.9% | 39.9% | < 0.001 |
Age (years) | 66 (62–76) | 65 (62–78) | 69 (67–79) | < 0.001 |
Body mass index (kg/m2) | 25.8 (22.2–28.8) | 26.8 (23.4–29.0) | 24.3 (21.7–28.4) | 0.191 |
Arterial hypertension | 36.2% | 35.3% | 36.1% | 0.789 |
Diabetes mellitus | ||||
Oral antidiabetic drugs | 8.9% | 7.2% | 5.5% | 0.006 |
Insulin | 2.3% | 2.8% | 2.6% | 0.530 |
Hypercholesterolaemia | 41.2% | 42.1% | 44.3% | 0.009 |
Renal dysfuntion | 1.4% | 2.3% | 2.1% | 0.254 |
Respiratory or lung disease | 2.1% | 2.3% | 1.9% | 0.187 |
Previous disabling stroke | 1.5% | 1.5% | 1.3% | 0.687 |
History of cancer | 1.4% | 1.9% | 2.5% | 0.030 |
Atrial fibrillation | 9.4% | 8.3% | 11.2% | < 0.001 |
Peripheral vascular disease | 4.8% | 4.3% | 4.9% | 0.556 |
Coronary artery disease | 9.3% | 10.2% | 8.4% | < 0.001 |
Left ventricular ejection fraction | 0.347 | |||
LVEF > 50% | 93.3% | 92.4% | 91.4% | |
LVEF 30–50% | 6.0% | 7.1% | 7.3% | |
LVEF < 30% | 0.7% | 0.5% | 1.3% | |
Previous surgery | 2.3% | 1.7% | 1.9% | 0.211 |
EuroSCORE II (%) | 1.2 (1.1–2.8) | 1.4(1.1–2.7) | 1.9 (1.3–3.1) | 0.387 |
Urgent procedure | 2.6% | 2.8% | 3.1% | 0.338 |
Surgical approach | RT | FS |
---|---|---|
n = 491 | n = 513 | |
Valve replacement n. tot = 1004 | ||
Cardiopulmonary bypass time (min) | 82 (79–98) | 84 (80–99) |
Cross-clamp time (min) | 59 (43–69) | 62 (45–71) |
n = 2898 | n = 1999 | |
---|---|---|
Valve repair n. tot = 4897 | ||
Cardiopulmonary bypass time (min) | 93 (62–99) | 81 (54–89) |
Cross-clamp time (min) | 75 (37–76) | 63 (36–73) |
Mitral valve pathology | Right-thoracotomy | Repair | Replacement |
---|---|---|---|
N = 3389 | N = 2898 | N = 491 | |
Degenerative | 2739 (80.8%) | 2540 (87.6%) | 199 (40.5%) |
Functional | 328 (9.6%) | 231 (7.9%) | 97 (19.7%) |
Reumathic | 247 (7.2%) | 97 (3.3%) | 150 (30.5%) |
Endocarditis | 28 (0.8%) | 3 (1.0%) | 25 (5.0%) |
Prosthesis dysfunction | 19 (0.5%) | 1 (0.03%) | 18 (3.6%) |
Miscellaneous | 28 (0.9%) | 26 (0.9%) | 2 (0.4%) |
Mitral valve pathology | Full Sternotomy | Repair | Replacement |
---|---|---|---|
N = 2512 | N = 1999 | N = 513 | |
Degenerative | 1781 (70.8%) | 1639 (81.9%) | 142 (27.6%) |
Functional | 367 (14.6%) | 179 (8.9%) | 188 (36.6%) |
Reumathic | 289 (11.5%) | 143 (6.6%) | 146 (28.4%) |
Endocarditis | 29 (1.15%) | 7 (0.3%) | 22 (4.2%) |
Prosthesis dysfunction | 17 (0.67%) | 10 (0.5%) | 7 (1.36%) |
Miscellaneous | 29 (1.15%) | 21 (1.0%) | 8 (1.5%) |
IABP | FS | Repair | Replacement | Inotropic support | Death 30 days |
---|---|---|---|---|---|
N = 48 | N = 26 | N = 22 | 28% | 18 | |
Degenerative | 15 | 1 | |||
Functional | 11 | 4 Repair and 5 Replacement | |||
Reumathic | 4 | 1 Replacement | |||
Endocarditis | 5 | 3 | 3 Repair | ||
Prosthesis dysfunction | 6 | 3 | 2 Replacement and 3 Repair | ||
Miscellaneous |
IABP | RT | Repair | Replacement | Inotropic support | Death 30 days |
---|---|---|---|---|---|
N = 51 | N = 22 | N = 29 | 35% | 3 | |
Degenerative | |||||
Functional | 13 | 18 | |||
Reumathic | 1 | 1 Replacement | |||
Endocarditis | 4 | 1 | |||
Prosthesis dysfunction | 5 | 9 | 2 Replacement | ||
Miscellaneous |
VA-ECMO | IABP | Inotropic support | Survival | |
---|---|---|---|---|
FS | 4 | 1 | ||
RT | 9 | 3 | 1 | |
Tot | 13 | 4 | 53% |